Palatin Technologies, Inc. (PINK:PTNT – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.54 and traded as high as $7.00. Palatin Technologies shares last traded at $5.60, with a volume of 7,665 shares changing hands.
Palatin Technologies Stock Performance
The company has a market capitalization of $145.66 million, a price-to-earnings ratio of -3.61 and a beta of 0.87. The business’s 50 day moving average price is $5.60 and its two-hundred day moving average price is $5.55.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Featured Stories
- Five stocks we like better than Palatin Technologies
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Is Trump Done? Shocking leak…
- Trump’s AI Secret: 100X Faster Than Nvidia
- What a Former CIA Agent Knows About the Coming Collapse
- Trade this between 9:30 and 10:45 am EST
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
